奈达铂与顺铂分别联合多西他赛治疗宫颈癌的临床疗效比较

Comparison of clinical efficacy of nedaplatin and cisplatin combined with docetaxel in the treatment of cervical cancer

目的比较奈达铂与顺铂分别联合多西他赛治疗宫颈癌的临床疗效.方法选取80例宫颈癌患者作为研究对象,依照化疗方案的不同分为观察组（40例）和对照组（40例）,观察组采用奈达铂联合多西他赛的化疗方案,而对照组则采用顺铂联合多西他赛的化疗方案,比较两组的临床疗效、化疗不良反应及住院相关指标等.结果观察组总有效率为85.0%,而对照组为77.5%,差异无统计学意义（x2=0.739,P=0.390）;观察组胃肠道反应（Ⅰ~Ⅳ级）发生率25.0%,低于对照组的82.5%,差异有统计学意义（x2=26.560,P=0.000）,肾毒性（Ⅰ~Ⅱ级）发生率2.5%,低于对照组的17.5%,差异有统计学意义（x2=5.000,P=0.025）;观察组住院时间（2.93＋0.39）d,短于对照组的（4.97±0.81）d,差异有统计学意义（t=14.352,P=0.000）;观察组骨髓抑制（Ⅰ~Ⅱ级）发生率43.0%,显著高于对照组的25.0%,差异有统计学意义（x2=4.381,P=0.036）;两组1年总生存率（OS）、无局部复发率（LRF）及无远处转移生存率（DMF）比较差异均无统计学意义（均P〉0.05）.结论奈达铂或顺铂与多西他赛联合应用于宫颈癌辅助化疗的疗效及短期预后相近的情况下,奈达铂的毒副反应更小,同时可缩短住院时间,患者更易接受,值得临床上推广.

 Objective To compare the clinical efficacy of nedaplatin and cisplatin combined with docetaxel in the treatment of cervical cancer.Methods 80 patients with cervical cancer were selected as the research subjects.According to different chemotherapy regimens,they were divided into observation group（40 cases）and control group（40 cases）.The observation group adopted nedaplatin combined with docetaxel chemotherapy regimen,while the control group used cisplatin plus docetaxel chemotherapy regimens.The clinical curative effect,adverse reaction of chemotherapy,hospitalization related indicators,etc were compared between the two groups.Results The total effective rate of the observation group was 85.0%,which of the control group was 77.5%,the difference was not statistically significant（x2=0.739,P=0.739）.The incidence rate of gastrointestinal reaction（Ⅰ-Ⅳ）in the observation group was 25.0%,which was lower than 82.5% in the control group（x2=26.560,P=0.000）.The incidence rate of renal toxicity（grade Ⅰ-Ⅱ）of the observation group was 2.5%,which was lower than 17.5% of the control group（x2=5.000,P=0.025）.The length of hospital stay of the observation group was（2.93 ±0.39）days,which was shorter than（4.97 ±0.81）days of the control group（t=14.352,P=0.000）.The incidence rate of bone marrow inhibition（grade Ⅰ-Ⅱ）of the observation group was 43.0%,which was significantly higher than 25.0% of the control group（x2=4.381,P=0.036）.1 year overall survival（OS）,no local recurrence rate（LRF）and no distant metastasis survival rate（DMF）between the two groups had no statistically significant differences（all P〉0.05）.Conclusion Efficacy of nedaplatin or cisplatin combined with docetaxel in adjuvant chemotherapy of cervical cancer has similar prognosis,nedaplatin has less toxicity,and can shorten the time of hospitalization,patients are more likely to accept,it is worthy of clinical promotion.